Laboratory Testing for Activated Protein C Resistance (APCR): An Update.
Favaloro EJ, Mohammed S, Vong R, Pasalic L.
Methods Mol Biol. 2023;2663:203-210. doi: 10.1007/978-1-0716-3175-1_11.
Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
Amiral J, Vissac AM, Seghatchian J.
Transfus Apher Sci. 2017 Dec;56(6):906-913. doi: 10.1016/j.transci.2017.11.021. Epub 2017 Nov 14.
Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
Van Cott EM, Soderberg BL, Laposata M.
Arch Pathol Lab Med. 2002 May;126(5):577-82. doi: 10.5858/2002-126-0577-APCRTF.
Laboratory Testing for the Evaluation of Phenotypic Activated Protein C Resistance.
Morimont L, Donis N, Bouvy C, Mullier F, Dogné JM, Douxfils J.
Semin Thromb Hemost. 2022 Sep;48(6):680-689. doi: 10.1055/s-0042-1758162. Epub 2022 Oct 12.
Activated protein C resistance and myocardial infarction.
Laffan MA.
Heart. 1998 Oct;80(4):319-21. doi: 10.1136/hrt.80.4.319.
Activated protein C resistance and factor V Leiden: a review.
Rosendorff A, Dorfman DM.
Arch Pathol Lab Med. 2007 Jun;131(6):866-71. doi: 10.5858/2007-131-866-APCRAF.
Factor V Leiden and activated protein C resistance.
Segers O, Castoldi E.
Adv Clin Chem. 2009;49:121-57. doi: 10.1016/s0065-2423(09)49006-1.
Activated protein C resistance and pregnancy loss.
Dawood F, Farquharson R, Quenby S.
Hosp Med. 2003 Jan;64(1):24-7. doi: 10.12968/hosp.2003.64.1.1840.
Activated protein C resistance: the most common risk factor for venous thromboembolism.
Sheppard DR.
J Am Board Fam Pract. 2000 Mar-Apr;13(2):111-5. doi: 10.3122/15572625-13-2-111.
Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states.
Nicolaes GA, Dahlbäck B.
Hematol Oncol Clin North Am. 2003 Feb;17(1):37-61, vi. doi: 10.1016/s0889-8588(02)00097-7.
